کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3925570 | 1253130 | 2007 | 11 صفحه PDF | دانلود رایگان |
ObjectivesTo evaluate the efficacy and tolerability of tolterodine extended release (ER) in men and women with overactive bladder (OAB).MethodsWe analyzed data from two 12-wk, placebo-controlled trials of tolterodine ER (4 mg QD). Patients completed 7-d bladder diaries and rated the urgency sensation associated with each micturition on a 5-point urgency rating scale. Micturitions were categorized by urgency rating: total (1–5), non-OAB (1–2), OAB (3–5), or severe OAB (4–5). Changes in micturitions during 24-h, daytime, and nocturnal intervals were assessed.ResultsAt baseline, 73% (547 of 745) of men and 57% (539 of 953) of women were continent. By week 12, tolterodine ER (n = 848) reduced OAB and severe OAB micturitions during 24-h, daytime, and nocturnal intervals in both sexes compared with placebo (n = 850). Adverse event rates were low and similar across treatment and gender.ConclusionsIn men and women with OAB, tolterodine ER reduced OAB and severe OAB micturitions, and was well tolerated.
Journal: European Urology - Volume 51, Issue 4, April 2007, Pages 1054–1064